OncoMatch/Clinical Trials/NCT07232602
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Is NCT07232602 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Pembrolizumab and MK-3120 for bladder cancer.
Treatment: MK-3120 · EV · Pembrolizumab · Rescue Medication — Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab. The goals of this study are to learn about: * The safety of the study treatment when given with standard treatment and if people tolerate it * The number of people who have the cancer respond (cancer gets smaller or goes away) with the new study treatment when given with standard treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Medical Center at Mission Bay ( Site 5044) · San Francisco, California
- Cleveland Clinic Taussig Cancer ( Site 5036) · Cleveland, Ohio
- Huntsman Cancer Institute ( Site 5041) · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify